Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax Inc (NVAX) is a clinical-stage biotechnology company pioneering vaccine development through recombinant nanoparticle technology and its proprietary Matrix-M adjuvant. This dedicated news hub provides investors and industry observers with timely updates on corporate developments, clinical trial progress, and regulatory milestones.
Our curated collection of Novavax news ensures access to official press releases, financial disclosures, and strategic partnership announcements. Users will find updates spanning vaccine candidate advancements, manufacturing expansions, and peer-reviewed research findings. Key content areas include quarterly earnings reports, FDA regulatory submissions, and global health collaborations.
Bookmark this page for streamlined tracking of Novavax's progress in addressing infectious diseases like COVID-19, influenza, and RSV. The resource is regularly updated to serve as your primary source for verified information about NVAX's scientific innovations and market positioning.
Novavax, Inc. has completed its regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its protein-based COVID-19 vaccine, NVX-CoV2373. This marks the first authorization submission for a protein-based COVID-19 vaccine in the U.K. The vaccine demonstrated high efficacy rates of 96.4% against the original virus and 89.7% overall in trials involving ~45,000 participants. Novavax plans to submit to additional global authorities, including the EU, Canada, and Australia, soon, with FDA submission expected by the end of 2021.
Novavax, Inc. (Nasdaq: NVAX) announces it will report its third quarter 2021 financial results on November 4, 2021, post-market close. The company will host a conference call at 4:30 p.m. EDT to discuss its operational highlights. Participants are encouraged to join early for a timely connection. A replay will be available from 7:30 p.m. EDT on the same day until November 11, 2021. Novavax focuses on developing innovative vaccines to combat serious infectious diseases, including COVID-19 and influenza.
Novavax, Inc. (Nasdaq: NVAX) announced that Dr. Vivek Shinde will present at the World Vaccine Congress Europe 2021 on October 20, 2021. The focus will be on the COVID-NanoFlu™ Combination Vaccine, a novel formulation that integrates the company's COVID-19 and NanoFlu™ vaccine candidates using the Matrix-M™ adjuvant.
The session is scheduled from 11:30 a.m. to 12:00 p.m. CET (5:30 a.m. to 6:00 a.m. EDT). For details, visit the Congress website.
On October 4, 2021, Novavax announced key leadership changes to strengthen its vaccine safety and clinical development teams. Dr. Denny Kim was appointed as Senior Vice President and Chief Safety Officer, with a focus on global vaccine safety. Other promotions include Dr. Raburn Mallory as Senior Vice President and Head of Clinical Development, and Dr. Marco Cacciuttolo as Senior Vice President of Process and Analytical Development. These appointments aim to enhance Novavax's capabilities as the company transitions to a commercial-stage organization, particularly in its pursuit of NVX-CoV2373, a COVID-19 vaccine.
On September 29, 2021, Novavax (Nasdaq: NVAX) announced its participation in the upcoming 2021 Maryland Life Sciences Bio Innovation Conference. The company will discuss its recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, during a panel titled Health Equity and Vaccine Confidence. This panel is scheduled for October 4, 2021, from 1:00 to 1:50 p.m. EDT. Notable speakers include Lisa M. Dunkle, M.D. from Novavax, alongside other experts from the Department of Defense and the University of Maryland.
On September 23, 2021, Novavax hosted HM King Carl XVI Gustaf and HM Queen Silvia at its Uppsala facility to discuss the progress of NVX-CoV2373, its COVID-19 vaccine candidate. The visit highlighted Novavax's commitment to global vaccination efforts, with a focus on its patented Matrix-M™ adjuvant, enhancing immune response. NVX-CoV2373 has shown high efficacy in Phase 3 trials, including 100% efficacy against severe disease. Novavax is also advancing its NanoFlu™ vaccine and is committed to addressing urgent global health needs.
Novavax, Inc. (Nasdaq: NVAX) announced the publication of complete results from its pivotal Phase 3 trial of NanoFlu™, a recombinant quadrivalent seasonal influenza vaccine, in The Lancet Infectious Diseases. The trial demonstrated NanoFlu's enhanced immunogenicity and safety compared to a leading influenza vaccine in older adults. The vaccine achieved all primary endpoints, showing significantly improved immune responses, including a 22-66% increase in antibody responses. The findings support NanoFlu's potential efficacy, particularly amid ongoing evaluations for a combination COVID-19-influenza vaccine.
Novavax, Inc. (Nasdaq: NVAX) has submitted a regulatory application for emergency use listing of its recombinant nanoparticle protein-based COVID-19 vaccine to the World Health Organization (WHO) in collaboration with the Serum Institute of India. This submission aims to facilitate equitable vaccine distribution globally, particularly through the COVAX Facility. The vaccine demonstrated high efficacy in pivotal Phase 3 trials, achieving 100% protection against severe disease and 90.4% overall efficacy. The NVX-CoV2373 vaccine is designed to be easily stored and administered, reinforcing Novavax's commitment to combating the pandemic.
Novavax, Inc. (Nasdaq: NVAX) announced its participation in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021, from 8:40 – 9:10 a.m. EDT. The discussion will feature the company's COVID-19 vaccine candidate, NVX-CoV2373. Key participants include Gregory M. Glenn, M.D., and John J. Trizzino. A replay of the session will be available on the company's website for 90 days. Novavax is advancing its developing vaccines, including NanoFlu™, which is set for regulatory submission.
Novavax (Nasdaq: NVAX) announced that John J. Trizzino, Executive Vice President, will participate in a fireside chat at Devex @ UNGA 76 on September 21, 2021, at 8:50 a.m. The discussion will focus on the status of Novavax' COVID-19 vaccine candidate, NVX-CoV2373, and initiatives for global vaccine access. The event runs from September 21-23 and will be livestreamed. Novavax is known for its innovative vaccine solutions aimed at serious infectious diseases.
